Regulus Therapeutics Receives Exclusive License for Intellectual Property to microRNA-33a and microRNA-33b to Treat Diseases that Include Atherosclerosis and Metabolic Syndrome Regulus Therapeutics Inc. announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a (miR-33a) and microRNA-33b (miR-33b) for metabolic diseases such as atherosclerosis and metabolic syndrome. [Regulus Therapeutics Inc. Press Release] Yale and Gilead Sciences Announce Cancer Research Collaboration Gilead Sciences, Inc. and Yale School of Medicine announced the formation of a multi-year research collaboration focused on the discovery of novel cancer therapies. [Gilead Sciences, Inc. Press Release] RXi Pharmaceuticals Aggressively Moves into Late-Stage Clinical Development with the Agreement to Acquire Apthera, Inc. RXi Pharmaceuticals Corporation and Apthera, Inc. announced the signing of a definitive merger agreement under which RXi will acquire Apthera. [RXi Pharmaceuticals Corporation Press Release] Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation Sanofi-aventis announced that it has successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation. [Sanofi-aventis Press Release] Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash Valeant Pharmaceuticals International, Inc. announced that it had made a proposal to the Board of Directors of Cephalon, Inc., to acquire Cephalon for $73.00 per share in cash. [Valeant Pharmaceuticals International, Inc. Press Release] Alnylam Achieves Key Technology Transfer Objective in Its Takeda Alliance; Earns $10 Million Payment Alnylam Pharmaceuticals, Inc. announced that it has earned a $10 million technology transfer payment from Takeda Pharmaceutical Company Limited as part of the strategic alliance the companies formed in May 2008. [Alnylam Pharmaceuticals, Inc. Press Release] Stem Cell Voice Box Transplant Trials Could Begin in 2013 Professor Martin Birchall announced that the first clinical trials for stem cell voice transplants will begin in 2013, thanks to a million pounds provided by the Medical Research Council. [Medical Research Council Press Release] CPRIT Awards $36.7 Million to UT Southwestern Investigators for Cancer Studies The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded more than $36.7 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer investigators. [University of Texas Southwestern Medical Center Press Release] Duncan Cancer Center Researchers Awarded $15.9 Million in New Round of CPRIT Grants Researchers in the National Cancer Institute-designated Dan L. Duncan Cancer Center at Baylor College of Medicine have received an additional $15.9 million in the new round of grants announced by the Cancer Prevention Research Institute of Texas (CPRIT). [Baylor College of Medicine Press Release] MRC Cash Boost to Maximize Discovery of Mouse Models of Human Diseases The Medical Research Council (MRC) has announced that it is to invest in excess of £60m over the next five years into mouse genetics research at MRC Harwell, Oxfordshire. [Medical Research Council Press Release] University of Michigan Creates State’s First Disease-Specific Human Embryonic Stem Cell Lines University of Michigan researchers have created the state’s first human embryonic stem cell lines that carry the genes responsible for inherited disease. [University of Michigan Press Release] TxCell Receives Approval for a Phase I/II Clinical Trial in Rheumatoid Arthritis TxCell SA announced the approval by AFSSAPS, the French regulatory agency, of its application to carry out a Phase I/II clinical trial of its second product candidate, TX-RAD. [TxCell SA Press Release] University of Pennsylvania Pioneers HIV Gene-Therapy Trial University of Pennsylvania researchers are still recruiting HIV-positive participants for a trial of a gene therapy approach intended to block HIV from entering human immune cells. [National Prevention Information Network Press Release] CaridianBCT Revolutionizes Cell Therapy Industry with New Cell Expansion Product CaridianBCT, a leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, announced the launch of a new product, the Quantum Cell Expansion System. [CaridianBCT, Inc. Press Release] Phase III Study of VX-770 in Children Ages 6 to 11 with a Specific Type of Cystic Fibrosis Showed Profound Improvements in Lung Function (FEV1) and Other Measures of Disease Through 24 Weeks Vertex Pharmaceuticals Incorporated announced positive results from a 24-week analysis of the ongoing Phase III ENVISION study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis. ENVISION was designed to evaluate VX-770 among children ages 6 to 11 with the G551D mutation in the CFTR gene. [Vertex Pharmaceuticals Incorporated Press Release] Glenmark’s Switzerland’s R&D Center Discovers a Monoclonol Antibody Targeting Leukemia and Lymphomas of B-Cell Origin Glenmark Pharmaceuticals S.A. announced the discovery and initiation of IND enabling studies of a Novel Biological Entity lead candidate, GBR 401, an anti-CD19 monoclonal antibody. [Glenmark Pharmaceuticals S.A. Press Release] Biogen Idec and Knopp Biosciences Announce Enrollment of the First Patient in a Global Phase III Study of Dexpramipexole for ALS Biogen Idec and Knopp Biosciences announced enrollment of the first patient in EMPOWER, a multi-national Phase III study evaluating the efficacy, safety and pharmacokinetics of dexpramipexole in patients with amyotrophic lateral sclerosis (ALS). [Biogen Idec Press Release] Aastrom Announces Key Manufacturing Milestone and New Generic Name for Its Cell Therapy Product Aastrom Biosciences, Inc. announced that it has completed an important product manufacturing milestone with the transfer of cell cassette manufacturing to ATEK Medical under the strategic partnership announced in October 2010. [Aastrom Biosciences, Inc. Press Release] Mount Sinai Hospital Opens New Centre for Regenerative Medicine Mount Sinai Hospital’s internationally respected Samuel Lunenfeld Research Institute announced the opening of a new Centre for Regenerative Medicine and Musculoskeletal Research at 25 Orde Street. [Samuel Lunenfeld Research Institute Press Release] Pediatric Nanomedicine Center Links Health Care and Engineering Physicians and engineers within a new center devoted to pediatric nanomedicine will develop targeted, molecular-sized nanoparticles as part of a unique approach to treating pediatric diseases. [Emory University Woodruff Health Sciences Center Press Release] Dendreon Statement on CMS Proposed Decision Memo for PROVENGE® Dendreon appreciates the work and diligent scientific review conducted by Centers for Medicare and Medicaid Services (CMS) that resulted in the draft decision memo, in which CMS proposes that the evidence is adequate to conclude that the use of autologous cellular immunotherapy with PROVENGE® improves health outcomes for Medicare beneficiaries with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer and thus is reasonable and necessary for that indication. [Dendreon Corporation Press Release] Generex Unveils Strategic Development Plan Generex Biotechnology Corporation held a press conference at the NASDAQ Marketsite in New York City to unveil management’s strategic development plan for the Company’s future growth. [Generex Biotechnology Corporation Press Release] Cancer Discovery: Call for Papers In response to a call from the scientific community, the American Association for Cancer Research is proud to launch Cancer Discovery, a highly visible and unique forum that will bring together the entire span of cancer science. [American Association for Cancer Research Press Release] |